

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
)	
Jean-Marc BALLOUL et al.)	Group Art Unit: 1652
)	
Application No.: 09/043,933)	Examiner: A. Salimi
)	
Filed: March 30, 1998)	
)	
For: PHARMACEUTICAL COMPOSITION)	
FOR TREATING PAPILLOMAVIRUS)	
TUMORS AND INFECTION)	

REPLY TO OFFICE ACTION

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated May 7, 1999, please enter the following
remarks:

REMARKS

This Reply is responsive the Office Action dated May 7, 1999, which requires that
the application comply with the sequence rules as set forth in 37 CFR §§ 1.821-1.825, and
sets forth a restriction requirement under 35 U.S.C. §§ 121 and 372.

Firstly, applicants note that submitted herewith is a copy of the sequence listing in
computer readable form, a statement that the computer readable and paper copies are the
same, and a declaration indicating that the submissions contain no new matter. Also
submitted separately is an amendment entering the substitute paper copy into the